RxDoctor Payments Data

William Hurtado-Santiago, MD

Nephrology · Mayaguez, PRNPI 1912022310

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $158,052 of the $190,609 with a category attached, or 82.9%. 30 manufacturers reported payments, led by AstraZeneca at 44.7% of the total. Among nephrology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$190,609in general payments, 2019–2025

Across 402 payments — averaging $474.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$85K
  • Calliditas Therapeutics US Inc.$40K
  • Boehringer Ingelheim$28K
  • Lilly USA, LLC$24K
  • Bayer$6K
  • Johnson & Johnson$3K
  • plus $5K from 24 others
$59,561in research payments, 2019–2025

Across 10 payments — averaging $5956.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$37K
  • AstraZeneca$18K
  • Vertex$4K
  • Boehringer Ingelheim International GmbH$302

What the payments were for

  • Consulting fees$2,0401%
  • Speaking & faculty fees$158,05283%
  • Travel & lodging$16,3789%
  • Food & beverage$13,9267%
  • Education$2140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$190,609 in reported general payments places this provider in the 95th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$31,300
Medicare patients
53
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol880$590,534
JardianceEmpagliflozin445$304,033
TarpeyoBudesonide12$196,480
KerendiaFinerenone178$127,603
GlyxambiEmpagliflozin/Linagliptin123$82,062
LokelmaSodium Zirconium Cyclosilicate63$53,542
Trijardy XrEmpaglifloz/Linaglip/Metformin74$44,870
Xigduo XrDapaglifloz Propaned/Metformin29$29,833
OzempicSemaglutide17$18,693
TrulicityDulaglutide15$14,752
Sevelamer Carbonate119$13,277
TradjentaLinagliptin19$11,075
EliquisApixaban14$8,496
XareltoRivaroxaban14$8,119
Sodium Polystyrene Sulfonate60$7,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$85,241$644,076943 claims
Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta$27,826$442,040661 claims
Calliditas Therapeutics US Inc.Tarpeyo$40,321$196,48012 claims
BayerKerendia$5,844$127,603178 claims
Lilly USA, LLCTrulicity$23,675$14,75215 claims
Johnson & JohnsonXarelto$2,677$8,11914 claims
ANI Pharmaceuticals, Inc.Valsartan$273$71240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Mayaguez

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →